Monash Investors’ Simon Shields on the difficulty in getting exposure to good IPOs, why Lovisa is a top pick, and the fund’s active position in Australian Strategic Metals.
/PRNewswire/ DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and.